3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Solid Tumor
1
Rectal Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Lung Diseases
1
Locally Advanced Cervical Cancer
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Erythrocytosis, Familial, 4
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Metastatic Urothelial Cancer
×
zimberelimab
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA